ATE411077T1 - Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen - Google Patents

Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen

Info

Publication number: ATE411077T1
Authority: AT; Austria
Prior art keywords: receptor ligand; inducing; compositions containing; treatment; gastrin
Prior art date: 2001-01-12

Application number

AT02708990T

Other languages

English (en)

Inventor

Stephen Brand

Original Assignee

Waratah Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-12

Filing date

2002-01-11

Publication date

2008-10-15

2002-01-11 Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE411077T1 publication Critical patent/ATE411077T1/de

Links

239000003446 ligand Substances 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract 2
102100021022 Gastrin Human genes 0.000 title 1
108010052343 Gastrins Proteins 0.000 title 1
230000001939 inductive effect Effects 0.000 title 1
230000009707 neogenesis Effects 0.000 title 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
239000008103 glucose Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000002035 prolonged effect Effects 0.000 abstract 2
108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
102000004859 Cholecystokinin Receptors Human genes 0.000 abstract 1
108090001085 Cholecystokinin Receptors Proteins 0.000 abstract 1
102000001301 EGF receptor Human genes 0.000 abstract 1
108060006698 EGF receptor Proteins 0.000 abstract 1
102000052874 Gastrin receptors Human genes 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
210000004153 islets of langerhan Anatomy 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02708990T 2001-01-12 2002-01-11 Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen ATE411077T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26163801P	2001-01-12	2001-01-12

Publications (1)

Publication Number	Publication Date
ATE411077T1 true ATE411077T1 (de)	2008-10-15

Family

ID=22994183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02708990T ATE411077T1 (de)	2001-01-12	2002-01-11	Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen

Country Status (13)

Country	Link
US (2)	US6992060B2 (de)
EP (1)	EP1351742B1 (de)
JP (1)	JP2004520345A (de)
KR (1)	KR20040064605A (de)
CN (1)	CN1486204A (de)
AT (1)	ATE411077T1 (de)
AU (1)	AU2002243501B2 (de)
CA (1)	CA2434330A1 (de)
DE (1)	DE60229352D1 (de)
ES (1)	ES2315350T3 (de)
IL (1)	IL156828A0 (de)
WO (1)	WO2002055152A2 (de)
ZA (1)	ZA200305347B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en) *	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
US20060014684A1 (en) *	2000-03-03	2006-01-19	University Technologies International Inc.	Novel uses of EGF
CA2434330A1 (en) *	2001-01-12	2002-07-18	Waratah Pharmaceuticals, Inc.	Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
WO2003018782A2 (en) *	2001-08-30	2003-03-06	Stem Cell Therapeutics Inc.	Differentiation of neural stem cells and therapeutic use theeof
WO2003024472A2 (en)	2001-09-14	2003-03-27	Stem Cell Therapeutics Inc.	Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
WO2003024471A2 (en) *	2001-09-18	2003-03-27	Stem Cell Therapeutics Inc.	Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
US7037504B2 (en) *	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
JP2005507919A (ja) *	2001-10-26	2005-03-24	ユニヴァーシティ・テクノロジーズ・インターナショナル・インコーポレーテッド	泌尿生殖器経路の病原感染を阻害するためのｅｇｆの使用
CN100448483C (zh) *	2002-05-24	2009-01-07	瓦拉塔药品公司	糖尿病的治疗
US20060234373A1 (en) *	2002-05-24	2006-10-19	Alex Rabinovitch	Treatment for diabetes
ES2334268T3 (es) *	2002-06-07	2010-03-08	Waratah Pharmaceuticals, Inc.	Procedimientos y composiciones para el tratamiento de la diabetes.
EP1837031B1 (de) *	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
CA2492442A1 (en) *	2002-07-31	2004-02-05	Stem Cell Therapeutics Inc.	Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
AU2003283004A1 (en) *	2002-10-22	2004-05-13	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
US20040229810A1 (en) *	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
US20060009516A1 (en) *	2002-10-24	2006-01-12	Mcgill University	Use of ingap for reversing diabetes
RU2005140518A (ru) *	2003-05-27	2007-07-10	Уэйрейта Фармасьютиклз, Инк. (Ca)	Композиции и способы, включающие соединения гастрина
US20080039379A1 (en) *	2003-05-27	2008-02-14	Waratah Pharmaceuticals, Inc.	Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US20070111932A1 (en) *	2003-07-31	2007-05-17	Stem Cell Therapeutics Inc.	Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2554458A1 (en) *	2004-01-30	2005-08-11	Waratah Pharmaceuticals, Inc.	The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
AU2005211847B2 (en)	2004-02-13	2011-02-24	Stem Cell Therapeutics Corp.	Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis
WO2006002532A1 (en) *	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
KR20070073879A (ko)	2004-10-07	2007-07-10	스템 셀 테라퓨틱스 코포레이션	임신 관련 화합물의 투여를 통한 다능성 줄기 세포의증식을 자극하는 방법
WO2007036033A1 (en) *	2005-09-27	2007-04-05	Stem Cell Therapeutics Corp.	Oligodendrocyte precursor cell proliferation regulated by prolactin
AU2006301892A1 (en) *	2005-10-07	2007-04-19	Waratah Pharmaceuticals, Inc.	Combined use of DPP IV inhibitors and gastrin compounds
MX2008007517A (es) *	2005-12-15	2009-03-04	Nestec Sa	Composiciones y metodos para preservar la funcion cerebral.
CA2633070C (en)	2005-12-19	2016-03-08	Pharmain Corporation	Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
KR20080103108A (ko) *	2006-03-17	2008-11-26	스템 셀 테라퓨틱스 코포레이션	신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
US20090312250A1 (en) *	2006-07-14	2009-12-17	Postech Academy-Industry Foundation	Epidermal growth factor increasing insulin secretion and lowering blood glucose
WO2008106775A1 (en) *	2007-03-02	2008-09-12	Waratah Pharmaceuticals Inc.	Combination treatment for diabetes using an egf receptor ligand and a gastrin compound
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) *	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CN102083451A (zh)	2008-06-12	2011-06-01	赛恩泰新公司	癌症的抑制
GB0820970D0 (en)	2008-11-17	2008-12-24	Syntaxin Ltd	Suppression of cancer
EP2560675A1 (de) *	2010-04-20	2013-02-27	Novo Nordisk A/S	Lang wirksame gastrinderivate
KR102027750B1 (ko) *	2018-05-03	2019-10-02	연세대학교 산학협력단	당 배출용 조성물
KR102508141B1 (ko) *	2019-07-01	2023-03-10	주식회사 연세대학교 바이오헬스기술지주회사	하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
KR102109385B1 (ko) *	2019-08-21	2020-05-12	연세대학교 산학협력단	당 배출용 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE38892B1 (en)	1973-03-28	1978-06-21	Ici Ltd	Pharmaceutical compositions
JPS6028994A (ja) *	1983-07-08	1985-02-14	Wakunaga Seiyaku Kk	〔２１―ロイシン〕ヒトウロガストロン
GB8409961D0 (en)	1984-04-17	1984-05-31	Searle & Co	Pharmaceutical compositions
US4686283A (en)	1985-04-16	1987-08-11	Syntex (U.S.A.) Inc.	Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
US5102789A (en)	1989-03-15	1992-04-07	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of epideramal growth factor in pichia pastoris yeast cells
US5158935A (en)	1989-05-12	1992-10-27	Chiron Corporation	Human epidermal growth factor having substitution at position 11
IE68593B1 (en)	1989-12-06	1996-06-26	Sanofi Sa	Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5434135A (en)	1990-08-02	1995-07-18	Indu Parikh	Growth factor compositions, preparation and use
AU2489992A (en)	1991-08-16	1993-03-16	Chiron Corporation	Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5885956A (en) *	1992-12-14	1999-03-23	Research Triangle Pharmaceuticals	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
WO1995019785A1 (en) *	1994-01-24	1995-07-27	Research Triangle Pharmaceuticals Ltd.	Treatment for juvenile diabetes
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en)	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
JP2002530064A (ja)	1998-11-19	2002-09-17	ミレニウムファーマシューティカルズ，インコーポレーテッド	Ｅｇｆ様核酸およびポリペプチド、ならびにその使用
CA2362593A1 (en)	1999-02-10	2000-08-17	Curis, Inc.	Pancreatic progenitor cells, methods and uses related thereto
US6610535B1 (en)	2000-02-10	2003-08-26	Es Cell International Pte Ltd.	Progenitor cells and methods and uses related thereto
CA2434330A1 (en)	2001-01-12	2002-07-18	Waratah Pharmaceuticals, Inc.	Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
US7202080B2 (en)	2001-03-29	2007-04-10	Ixion Biotechnology, Inc.	Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US7037504B2 (en)	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
US20060234373A1 (en)	2002-05-24	2006-10-19	Alex Rabinovitch	Treatment for diabetes
ES2334268T3 (es)	2002-06-07	2010-03-08	Waratah Pharmaceuticals, Inc.	Procedimientos y composiciones para el tratamiento de la diabetes.
EP1837031B1 (de)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en)	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
AU2003283004A1 (en)	2002-10-22	2004-05-13	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
AU2003228097A1 (en)	2003-04-28	2004-11-23	Pirelli Pneumatici S.P.A.	Pneumatic tire provided with a multi-layered tread and process for its manufacture
RU2005140518A (ru)	2003-05-27	2007-07-10	Уэйрейта Фармасьютиклз, Инк. (Ca)	Композиции и способы, включающие соединения гастрина
CA2554458A1 (en)	2004-01-30	2005-08-11	Waratah Pharmaceuticals, Inc.	The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2006002532A1 (en)	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
AU2006301892A1 (en)	2005-10-07	2007-04-19	Waratah Pharmaceuticals, Inc.	Combined use of DPP IV inhibitors and gastrin compounds
EP1971363A1 (de)	2005-12-02	2008-09-24	Waratah Pharmaceuticals, Inc.	Kombinationsbehandlungen mit gastrin-agonisten für diabetes und verwandten erkrankungen
WO2007095737A1 (en)	2006-02-21	2007-08-30	Waratah Pharmaceuticals Inc.	Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

2002
- 2002-01-11 CA CA002434330A patent/CA2434330A1/en not_active Abandoned
- 2002-01-11 CN CNA028036824A patent/CN1486204A/zh active Pending
- 2002-01-11 IL IL15682802A patent/IL156828A0/xx unknown
- 2002-01-11 ES ES02708990T patent/ES2315350T3/es not_active Expired - Lifetime
- 2002-01-11 KR KR10-2003-7009347A patent/KR20040064605A/ko not_active Application Discontinuation
- 2002-01-11 AU AU2002243501A patent/AU2002243501B2/en not_active Ceased
- 2002-01-11 WO PCT/US2002/000685 patent/WO2002055152A2/en active Application Filing
- 2002-01-11 DE DE60229352T patent/DE60229352D1/de not_active Expired - Fee Related
- 2002-01-11 EP EP02708990A patent/EP1351742B1/de not_active Expired - Lifetime
- 2002-01-11 AT AT02708990T patent/ATE411077T1/de not_active IP Right Cessation
- 2002-01-11 JP JP2002555881A patent/JP2004520345A/ja active Pending
- 2002-01-11 US US10/044,048 patent/US6992060B2/en not_active Expired - Fee Related
2003
- 2003-07-10 ZA ZA200305347A patent/ZA200305347B/en unknown
2005
- 2005-11-14 US US11/273,615 patent/US7476388B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL156828A0 (en)	2004-02-08
EP1351742A2 (de)	2003-10-15
WO2002055152A3 (en)	2003-04-10
CN1486204A (zh)	2004-03-31
ZA200305347B (en)	2004-10-11
KR20040064605A (ko)	2004-07-19
US20060234932A1 (en)	2006-10-19
ES2315350T3 (es)	2009-04-01
DE60229352D1 (de)	2008-11-27
EP1351742B1 (de)	2008-10-15
CA2434330A1 (en)	2002-07-18
WO2002055152A8 (en)	2002-11-14
JP2004520345A (ja)	2004-07-08
US7476388B2 (en)	2009-01-13
WO2002055152A2 (en)	2002-07-18
AU2002243501B2 (en)	2007-11-22
US20020098178A1 (en)	2002-07-25
WO2002055152A9 (en)	2003-01-23
US6992060B2 (en)	2006-01-31

Publication	Publication Date	Title
ATE411077T1 (de)	2008-10-15	Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen
ID28783A (id)	2001-07-05	Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain
ATE375166T1 (de)	2007-10-15	Zusammensetzungen und verfahren zur behandlung von diabetes
ATE406179T1 (de)	2008-09-15	Sauerstoff-abgabe mittel und ihre anwendung
DE60326002D1 (de)	2009-03-12	Behandlung von diabetes.
DE60331236D1 (de)	2010-03-25	Orale zusammensetzungen zur behandlung von diabetes
ZA9811241B (en)	1999-06-09	New piperidinyl-substituted pyridylalkane alkene and alkine carboxamides
ATE314046T1 (de)	2006-01-15	Mittel zum oxidativen färben von keratinfasern, welche ein kationisches polyvinyllactam enthalten
NI200600290A (es)	2007-08-07	Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
BRPI0408229A (pt)	2006-02-21	preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação
SG143042A1 (en)	2008-06-27	Treatment for diabetes
BR9913284A (pt)	2001-05-15	Métodos para administrar peptìdeos insulinotrópicos
WO2002099057A3 (en)	2003-07-24	Sams modifiers of the p53 pathway and methods of use
PT1349856E (pt)	2005-09-30	Compostos de isoindolina-1-ona activadores da glicocinase
BR0309278A (pt)	2005-04-26	Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
FI972287A (fi)	1997-05-29	Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten.
ATE362925T1 (de)	2007-06-15	Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2- familie exprimieren
WO2002053106A3 (en)	2002-12-19	Autoantigen composition
IS1966B (is)	2004-12-15	Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DK0988302T3 (da)	2003-06-02	Benzonaphthyridiner
DK1643999T3 (da)	2012-01-02	Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
RS52011B (sr)	2012-04-30	Nova primena derivata taksoida
NO985571L (no)	1999-01-27	Legemiddel for autoimmunsykdommer
ATE215525T1 (de)	2002-04-15	Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
ATE249172T1 (de)	2003-09-15	Medizinisches gerät

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties